Home › Atrial Fibrillation › NCT06376916
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RecruitingPhase 3
Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age \> 18 years or older * Able to provide informed consent * Primary diagnosis AFF RVR greater than or equal to 120 bpm * Diltiazem as rate control agent * English speaking Exclusion Criteria: * Hemodynamically unstable patients (SBP \<90, MAP \<65) * Impaired consciousness * End stage renal disease on hemodialysis or peritoneal dialysis * Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging * Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis * Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response * Acute myocardial infarction * Pregnancy defined as a positive urine HCG (human chorionic gonadotropin) * Contraindications to magnesium sulfate (including myasthenia gravis) * Allergy or sensitivity to any study drugs * Previously enrolled in this trial during a different patient encounter * Withdrew from study
About the study
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
What is being tested
- Magnesium Sulfate 2 G (drug)
- Magnesium Sulfate 4 G (drug)
- Saline (drug)
Sponsor: Wake Forest University Health Sciences · Participants: 153 · Started: Oct 7, 2024
Contact the study team
- Marc McDowell, PharmD · Phone: (708) 684-1078
Official record on ClinicalTrials.gov — NCT06376916
Locations in the U.S.
| Illinois | Advocate Christ Medical Center Emergency Department (ACMC ED), Oak Lawn |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.